Insights Into Acute Lymphoblastic Leukemia (ALL) 2025
Perspectives of community physicians on the treatment of ALL
Faculty Chair
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Faculty Chair
Daniel DeAngelo, MD
Dana-Farber Cancer Institute, Boston, MA, USA
Faculty Chair
Matthew Wieduwilt, MD
Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Lori Muffly, MD
Stanford University, Stanford, CA, USA
Faculty Chair
Caspian Oliai, MD
UCLA Health, Los Angeles, CA, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Gregory Roloff, MD
UChicago Medicine, Chicago, IL, USA
Faculty Chair
Ibrahim Aldoss, MD
City of Hope, Duarte, CA, USA
Faculty Chair
Rawan Faramand, MD
Moffitt Cancer Center, Tampa, FL, USA
More Information
- Virtual series
More Information
- Virtual series
More Information
- Virtual series
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Virtual series
- California, Nevada
More Information
- Virtual series
- Florida
More Information
- Virtual series
- Texas
More Information
- Virtual series
- Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual series
More Information
- Phoenix, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Virtual series
More Information
- Virtual series
More Information
- Virtual series
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of ALL
- Disease state and data presentations were developed in conjunction with a national or regional oncology expert
- Insights on the following therapies were obtained: blinatumomab, ponatinib, inotuzumab ozogamicin, liposomal vincristine, and chimeric antigen receptor (CAR) T-cell therapy
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collection was accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprised 10–15 medical oncologists representative of each region